# Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

> **NCT06982040** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 80 (estimated)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** NTQ5082 capsules 100 mg
- **DRUG:** NTQ5082 capsules 200 mg
- **DRUG:** NTQ5082 capsules 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06982040
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982040, "Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06982040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*